Janice Smith

Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease

Alexandria Wise-Brown, Sharon A. Brangman, J. Neil Henderson, Monica Willis‐Parker et autres

Clinical trial participation across disease areas, including Alzheimer's disease (AD), has been biased towards White participants of European ancestry. To support clinical decision-making across diverse populations, we must recognize and address barriers to trial participation. To inform the design of ALUMNI AD, …

us, gb, ch (code pays fourni par la source)

ALUMNI AD Study Design: Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer’s Disease (S26.006)

Sheila Seleri, Sharon A. Brangman, J. Neil Henderson, Monica Parker et autres

Objective: We aim to evaluate efficacy, safety, and pharmacokinetics/pharmacodynamics of gantenerumab in amyloid-positive participants with early symptomatic Alzheimer’s disease ([AD]; ie, mild cognitive impairment [MCI] due to AD or mild AD dementia) in historically underrepresented populations. Gantenerumab is a fully human anti-amyloid …

ch, us, de (code pays fourni par la source)

Data from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Abstract Neuroblastoma is a frequently lethal childhood tumor in which MYC gene deregulation, commonly as MYCN amplification, portends poor outcome. Identifying the requisite biopathways downstream of MYC may provide therapeutic opportunities. We used transcriptome analyses to show that MYCN-amplified neuroblastomas have coordinately …

us, au (code pays fourni par la source)

Supplementary Table 1, Supplementary Figures 1-5 from Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma

Catherine A. Burkhart, Fujiko Watt, Jayne Murray, Marina Pajic et autres

Supplementary Table 1, Supplementary Figures 1-5 from Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma

Supplementary Figure Legends 1-3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure Legends 1-3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure 1 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure 1 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure 3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure 3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure 2 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure 2 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure Legends 1-3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure Legends 1-3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure 3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure 3 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure 2 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure 2 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Supplementary Figure 1 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma

Michael D. Hogarty, Murray D. Norris, Kimberly A. Davis, Xueyuan Liu et autres

Supplementary Figure 1 from ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma